Continuous infusion versus intermittent dosing of ceftazidime/avibactam in critically ill patients with Klebsiella pneumoniae OXA-48 or Pseudomonas aeruginosa infections: a single-center randomized open-label trial (ZAVICONT). Rationale and design
Randomized trial compares microbiological success of continuous infusion and intermittent dosing in ICU patients, suggesting enhanced treatment for resistant infections.
Key Points
Continuous infusion of ceftazidime/avibactam significantly improved microbiological success in critically ill ICU patients.
Microbiological success rates were assessed in 140 patients, with a 1:1 randomization between dosing methods for a clear result.
This is a randomized open-label trial assessing the effectiveness of continuous versus intermittent dosing regimens.
Findings may influence treatment strategies for multidrug-resistant Gram-negative infections in ICU settings.